Form 4: REGENXBIO CEO Granted Significant Equity Awards

REGENXBIO Inc.'s CEO, Curran Simpson, was granted 144,864 restricted stock units and 233,651 stock options, vesting over several years.

Summary

• Curran Simpson, the Chief Executive Officer and a Director of REGENXBIO Inc., received new equity awards on January 6, 2026.
• The awards include 144,864 shares of common stock underlying a time-based Restricted Stock Unit (RSU) award, granted at a price of $0.00.
• The RSU award vests in four equal annual installments of 25% each, on January 6, 2027, January 6, 2028, January 6, 2029, and January 6, 2030, contingent upon continuous service to the Issuer.
• Additionally, 233,651 stock options were granted with an exercise price of $14.18 and an expiration date of January 6, 2036.
• The stock options vest 25% after 12 months of continuous service, with the remaining balance vesting in equal monthly installments over the 36 months following January 6, 2027.
• Following these transactions, Curran Simpson beneficially owns 342,467 shares of common stock and 233,651 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing reports routine executive compensation in the form of equity grants, which is generally positive for aligning management and shareholder interests over the long term. There are no negative surprises or significant operational news, making it a neutral to slightly positive event.

Positives

• The significant equity grants to the CEO align management's long-term financial interests with those of shareholders, incentivizing sustained value creation.
• The multi-year vesting schedules for both RSUs (until 2030) and stock options (vesting through 2030, expiring 2036) promote executive retention and focus on long-term strategic goals.
• These grants demonstrate continued commitment from the CEO to the company's future performance and growth.

Risks

• The vesting of both the RSU award and stock options is contingent upon Curran Simpson providing continuous service to REGENXBIO Inc., meaning the full value is not realized if employment ceases prematurely.
• The value of the stock options is dependent on REGENXBIO's common stock price exceeding the exercise price of $14.18 in the future.

Future Outlook

The equity grants with multi-year vesting schedules indicate a long-term strategic outlook for REGENXBIO, tying executive incentives to sustained future performance and growth, suggesting management's confidence in the company's trajectory.

Industry Context

These equity grants are a standard practice in the biotechnology and pharmaceutical industry to attract, retain, and incentivize key executives. Such compensation structures are common across publicly traded companies in the sector, reflecting a commitment to leadership stability and performance-based rewards, aligning executive interests with long-term innovation and market success.

Related Party Transactions

• The equity grants to CEO Curran Simpson are considered related party transactions as they involve compensation to an executive officer and director.

Stakeholder Impact

• Shareholders: The grants align the CEO's long-term financial interests with shareholder value creation, potentially leading to more sustained strategic decisions and a focus on long-term growth.
• Employees: May signal stability in leadership and a commitment to long-term company growth, which can positively impact employee morale and retention.

Next Steps

• Curran Simpson's continued service to REGENXBIO Inc. is required for the vesting of the equity awards.
• Monitoring of REGENXBIO's stock performance relative to the option exercise price of $14.18 will be relevant for the value realization of the stock options.

Key Dates

Recommendation

This Form 4 filing details routine executive equity compensation and does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The grants align management incentives with long-term shareholder value, which is a positive, but not a catalyst for a 'buy' or 'sell' decision on its own.

Keywords

REGENXBIO, RGNX, SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, CEO Compensation, Curran Simpson, Executive Compensation